Effect of melatonin administration on
subjective sleep quality in chronic
obstructive pulmonary disease
D.M. Nunes
1, R.M.S. Mota
2, M.O. Machado
3, E.D.B. Pereira
3, V.M.S. de Bruin
3and
P.F.C. de Bruin
31
Departamento de Farmácia,
2Departamento de Estatística e Matemática Aplicada,
3Departamento de
Medicina Clínica, Universidade Federal do Ceará, Fortaleza, CE, Brasil
Correspondence to: P.F.C. de Bruin, Departamento de Medicina Clínica, Universidade Federal do Ceará,
Rua Prof. Costa Mendes, 1608, 4° andar, 60430-040 Fortaleza, CE, Brasil
E-mail: pfelipe@superig.com.br
Disturbed sleep is common in chronic obstructive pulmonary disease (COPD). Conventional hypnotics worsen nocturnal hypoxemia and, in severe cases, can lead to respiratory failure. Exogenous melatonin has somnogenic properties in normal subjects and can improve sleep in several clinical conditions. This randomized, double-blind, placebo-controlled study was carried out to determine the effects of melatonin on sleep in COPD. Thirty consecutive patients with moderate to very severe COPD were initially recruited for the study. None of the participants had a history of disease exacerbation 4 weeks prior to the study, obstructive sleep apnea, mental disorders, current use of oral steroids, methylxanthines or hypnotic-sedative medication, nocturnal oxygen therapy, and shift work. Patients received 3 mg melatonin (N = 12) or placebo (N = 13), orally in a single dose, 1 h before bedtime for 21 consecutive days. Sleep quality was assessed by the Pittsburgh Sleep Quality Index (PSQI) and daytime sleepiness was measured by the Epworth Sleepiness Scale. Pulmonary function and functional exercise level were assessed by spirometry and the 6-min walk test, respectively. Twenty-five patients completed the study protocol and were included in the final analysis. Melatonin treatment significantly improved global PSQI scores (P = 0.012), particularly sleep latency (P = 0.008) and sleep duration (P = 0.046). No differences in daytime sleepiness, lung function and functional exercise level were observed. We conclude that melatonin can improve sleep in COPD. Further long-term studies involving larger number of patients are needed before melatonin can be safely recommended for the management of sleep disturbances in these patients.
Key words: Chronic obstructive pulmonary disease; Melatonin; Sleep
Presented at the XI Congresso Brasileiro do Sono, Fortaleza, CE, Brazil, November 11-14, 2007.
Received May 10, 2008. Accepted October 14, 2008
Introduction
Chronic obstructive pulmonary disease (COPD) is a debilitating respiratory condition characterized by progres-sive airflow limitation primarily caused by cigarette smok-ing. It represents a major cause of morbidity and mortality worldwide (1-3).
Poor-quality sleep is a common complaint in COPD. Objective evidence of disturbed sleep, including reduced sleep efficiency, delayed sleep onset, reduced total sleep time, and frequent periods of wakefulness, has been well
follow-ing one night’s sleep deprivation in COPD patients (8). Conventional hypnotics should not be used in hypercap-nic patients with COPD because they may precipitate respiratory failure due to further inhibition of ventilatory responses. In normocapnic patients, benzodiazepines have been reported to increase frequency and duration of nocturnal hypoxemia (9).
The pineal hormone melatonin is the neuroendocrine transducer of the light-dark cycle. It plays an important role in the regulation of human circadian rhythms and may have sleep-inducing activity in humans (10). There is also considerable evidence that melatonin has immunomodu-latory and anti-oxidant properties (11). Exogenous melato-nin administration has been shown to improve sleep in several medical conditions, including asthma (12,13), al-though reported effects have been variable (14,15). The safety of melatonin treatment up to at least 3 months has been confirmed by a recent meta-analysis (15).
The aim of the present study was to evaluate the effect of 21 days of melatonin administration on subjective sleep quality in ambulatory patients with clinically stable COPD.
Subjects and Methods
Subjects
Thirty consecutive patients regularly attending the Res-piratory Outpatient Clinic at the University Hospital of the Federal University of Ceará, Brazil, were initially recruited for the study. Individuals wereeligible to participate if they were 40 years of age or older, had a medical diagnosis of stage II to IV COPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (1) and were considered to be in a clinically stable condition by the attending physician. Exclusion criteria were disease exac-erbation 4 weeks prior to the study, presence of obstructive sleep apnea or mental disorders, current use of oral ster-oids, methylxanthines or hypnotic-sedative medication, nocturnal oxygen therapy, and shift work. Twenty-five pa-tients completed the study protocol and were included in the final analysis. The study protocol was approved by the local Research Ethics Committee and written informed consent was obtained from all patients.
Study design
This was a randomized, double-blind, parallel-group, placebo-controlled study of individuals with COPD. Ini-tially, quality of sleep and daytime sleepiness were as-sessed by the Pittsburgh Sleep Quality Index (PSQI) and the Epworth Sleepiness Scale (ESS), respectively; lung function was evaluated by spirometry, and functional exer-cise level was measured by the 6-min walk test. Patients
were asked to indicate their habitual in- and out-of-bed time, during the previous 5 days. They were also in-structed to keep a diary with records of their in- and out-of-bed times during the 21-day study period. Patients were then randomized to the melatonin or placebo group. Fast-release 3 mg melatonin (Natural Wealth, USA) or placebo was supplied in identical capsules to be taken in a single dose 1 h before bedtime for 21 consecutive days. Other medications were maintained as prescribed by the attending physician. Subjects were not required to keep any specific sleep-wake schedule. Assessment of sleep quality, daytime sleepiness, lung function and functional exercise level was repeated at the end of the treatment for comparison. All measurements were performed between 9 and 12 am. In- and out-of-bed times for the last 5 days of treatment were averaged for each group and compared with pre-treatment values. Subjects were contacted by telephone at least once a week to check for adverse effects and compliance. Patients and investigators were unaware of treatment allocation at all times.
Outcomes
The primary outcome measure was quality of sleep assessed by the PSQI. The PSQI is a seven-component scale, each one dealing with a major aspect of sleep: 1) subjective sleep quality; 2) sleep latency; 3) sleep dura-tion; 4) sleep efficiency; 5) sleep disturbance; 6) use of sleep medication, and 7) daytime dysfunction. These com-ponents are weighted equally on a 0-3 scale, with a global score ranging from 0-21. A global PSQI score above five has been found to have a sensitivity of 89.6% and specificity of 86.5% in differentiating good from poor sleepers (16). Component number 6 always scored zero because individuals on sleep medications were not in-cluded in this study.
Secondary outcome measures were daytime somno-lence, functional exercise level and lung function. Daytime somnolence was assessed by the ESS, a questionnaire that measures a subject’s expectation of dozing in eight hypothetical situations. Dozing probability ratings range from zero (none) to three (high probability). A total score of 10 or more is considered to be indicative of excessive daytime sleepiness (17).
the established time of 6 min. The test wasperformed under the control of one of the investigators who encour-aged thepatients. At the end of 6 min,the investigator measured the distance walked by the patient (18).
Spirometry was performed according to recommended techniques. Measurements included FEV1, FVC, and FEV1/FVC ratioand results were compared with previ-ously published normal values (19).
Statistical analysis
Data were examined for normality using the Shapiro-Wilk test. Between-group comparisons of age and body mass index were made with the unpaired Student t-test. Past cigarette consumption in both groups was compared by the Mann-Whitney test. ESS scores, spirometric re-sults, 6MWD, and in- and out-of-bed times, as well as within-group comparisons (before and after treatment) of the same variables of the melatonin and placebo groups were compared with two-way ANOVA. Differences in glo-bal PSQI scores as well as in PSQI component scores before and after treatment were analyzed for each group using the Wilcoxon test. Between-group comparisons of global PSQI scores and PSQI component scores were made with the Mann-Whitney test. Additionally, patients were divided into two categories: good sleepers (PSQI ≤5) and poor sleepers (PSQI >5). Distribution of good and poor sleepers in melatonin and placebo groups were
compared using the Fisher exact test. Within-group com-parisons of good and poor sleepers (before and after treatment) were made using the MacNemar test. Statisti-cal analysis was performed with the StatistiStatisti-cal Package for Social Sciences (20). Data are reported as mean ± SD and the level of significance was set at P < 0.05.
Results
Thirty patients with stage II to IV COPD were initially recruited for the study. Five individuals (2 from the melato-nin group and 3 from the placebo group) were removed from the study because of an exacerbation of COPD (2 patients), hospitalization for non-respiratory reasons (1 pa-tient), alleged adverse effects of treatment (1 papa-tient), and loss of follow-up (1 patient). Demographic and clinical characteristics of the 25 patients who finished the protocol are shown in Table 1. No significant differences were found between the two groups with respect to age, smoking history, body mass index, global PSQI scores, in- and out-of-bed times, ESS score, 6MWD, FEV1 % predicted and FEV1/FVC ratio before treatment (P > 0.05). Mean FVC % predicted was lower in the placebo group compared with the melatonin group before treatment (P = 0.020).
Outcome measures
On initial assessment, 16 patients (8 from the
melato-Table 1. Table 1. Table 1. Table 1.
Table 1. Demographic characteristics, quality of sleep, daytime sleepiness, pulmonary function, and functional exercise level before and after treatment with melatonin or placebo.
Melatonin (N = 12) Placebo (N = 13)
Before After Before After
Gender (male/female) 7 / 5 7 / 6
Age (years) 64.17 ± 9.9 67.38 ± 8.1
Smoking history (pack-years) 42.87 ± 25.8 44.92 ± 29.9
BMI (kg/m2) 23.87 ± 4.2 23.80 ± 4.2 24.10 ± 4.0 24.14 ± 4.0
PSQI 7.75 ± 4.0* 4.58 ± 1.2* 6.38 ± 3.0 5.54 ± 2.2
Good/poor sleepers 4/8*** 11/1*** 5 / 8 7 / 6
In-bed time (decimal hours) 22.65 ± 0.94 22.36 ± 1.31 22.20 ± 1.05 22.48 ± 0.83 Out-of-bed time (decimal hours) 5.25 ± 0.82 5.43 ± 0.92 5.43 ± 1.37 5.57 ± 0.88
ESS 7.83 ± 5.5 7.17 ± 5.1 7.31 ± 3.9 8.08 ± 4.9
FVC (% predicted) 83.67 ± 12.2** 83.02 ± 18.5 68.72 ± 16.3** 71.64 ± 15.3 FEV1 (% predicted) 57.52 ± 14.0 56.81 ± 19.2 46.78 ± 17.0 48.83 ± 17.3 FEV1/FVC ratio 54.97 ± 8.7 54.26 ± 10.3 52.83 ± 10.5 52.96 ± 10.6 6MWD (m) 356.3 ± 70.0 361.6 ± 58.6 332.8 ± 67.0 340.7 ± 55.4
nin group) were classified as poor sleepers. A significant improvement in the relative frequency of good vs poor sleepers was observed after melatonin treatment (P = 0.016), but not after placebo (P > 0.05). A trend toward an improvement in the distribution of good vs poor sleepers was detected in the group treated with melatonin com-pared with placebo (P = 0.073). Global PSQI score was significantly improved by melatonin treatment (P = 0.012; Table 1). Global PSQI scores before and after treatment for individuals in both groups are shown in Figure 1. A significant reduction in the PSQI component sleep latency (P = 0.008), an increase in sleep duration (P = 0.046) and a trend toward an improvement in sleep efficiency (P = 0.057) were found after melatonin treatment.
Excessive daytime sleepiness was detected in 5 sub-jects from the melatonin group and in 4 subsub-jects from the placebo group. Treatment with melatonin or placebo did not significantly change ESS scores. No significant differ-ences were observed in lung function parameters or in the 6MWD after treatment with melatonin or placebo (Table 1).
Adverse effects
A subject from the placebo group left the study be-cause of an alleged side-effect (tongue swelling). Four of the 25 cases included in the final analysis reported
ad-verse effects: mild headache (1 subject from the melato-nin group); dryness of the mouth (1 subject from the melatonin group and 1 from the placebo group) and loss of appetite (1 subject from the placebo group).
Discussion
The results of this study show that 3 mg melatonin taken 1 h before bedtime can improve sleep in patients with moderate to very severe COPD. To our knowledge, this is the first study on melatonin and sleep in ambulatory patients with COPD. Previously, Shilo and co-workers (21) conducted a pilot study on the effects of exogenous mela-tonin on sleep quality in 8 adult patients hospitalized in the pulmonary intensive care unit with respiratory failure caused by exacerbation of COPD or with pneumonia. Patients received either 3 mg of controlled-release melatonin or placebo at 10 pm. Sleep quality was evaluated by actigraphy. Treatment with melatonin improved both the duration and quality of sleep.
It is generally accepted that melatonin administered during the day, when its endogenous levels are low, has somnogenic properties (10,22). When used near the time of habitual sleep, melatonin has produced less consistent results. Nocturnal administration has been reported to pro-mote sleep (23,24), to have no significant clinical benefit (25) or to even increase wake time after sleep onset (26). Such variability may be related to differences in inclusion and exclusion criteria, outcome measures, hormone dose, and routes and timing of its administration. A recent meta-analysis based on data derived from 17 studies indicates that melatonin can produce small but significant benefits in sleep onset latency, sleep efficiency and sleep duration (14). Importantly, such improvements seem to be associ-ated with better performance in tests of attention, concen-tration, fine motor activity, and reaction time and with the sensation of improved daytime well being (27). In addition to its sleep-inducing effects, melatonin has chronobiotic properties, i.e., the ability to phase-shift the human circa-dian system by advance or delay according to a phase-response curve or to re-entrain a desynchronized circadian rhythm (28). Both the sleep-inducing and the circadian effect may provide useful tools for improving sleep in COPD and other similar clinical conditions.
The mechanism for melatonin sleep-inducing effect has not been fully elucidated. Involvement of a GABAergic mechanism has been suggested by experimental evi-dence of melatonin interaction with central benzodiaz-epine receptors (29). However, a clinical trial with flumazenil, a benzodiazepine antagonist, failed to dem-onstrate a decrease in hypnotic and hypothermic effects
Figure 1. Figure 1. Figure 1. Figure 1.
of melatonin (30). Plasma cGMP shows circadian varia-tion, with peak levels being observed during nocturnal sleep. Melatonin administration promotes an increase in cGMP, with peak levels coinciding with melatonin ac-rophase. Moreover, peak plasma levels of melatonin and cGMP show a positive correlation with sleepiness, point-ing to an involvement of cGMP in melatonin hypnotic action (31). It has also been suggested that melatonin may act to facilitate sleep by inhibiting the circadian drive for waking that comes from the suprachiasmatic nucleus (10). This is supported by evidence from studies in both day-active animals (32) and humans (33) that the circa-dian pacemaker promotes wakefulness at certain times of day, together with evidence that neuronal firing of the mammalian suprachiasmatic nucleus is inhibited by su-prachiasmatic nucleus Mel1a receptor-specific melatonin
binding (34).
On average, the subjects in the present study did not present daytime somnolence. The scarce literature pub-lished on daytime sleepiness in patients with COPD is conflicting. Cormick et al. (35) evaluated sleep quality and daytime sleepiness in fifty patients with COPD and re-ported difficulty in getting tosleep and staying asleep and daytime sleepiness compared with age-matched con-trols without symptomatic lung disease. Interestingly, more than twice as many patients (28%) as controls (10%) reportedregular use of hypnotics. Orr and co-workers (36) studied 14 patients with COPD and chronic hypox-emia and were unable to find any evidence of daytime sleepiness, despite polysomnographic demonstration of a short sleep time and an increased number of arousals from sleep. In the present study, improved sleep after melatonin treatment was not accompanied by any signifi-cant change in sleepiness scores. It has been recognized that, in contrast to common hypnotics, melatonin does not produce a rapid increase in subjective sleepiness or major impairments in cognitive performance (37). A study comparing the effects of melatonin and temazepam on sleepiness and cognitive performance showed that while temazepam causes an abrupt but short-lived increase in subjective sleepiness, melatonin gradually increases sleepiness. A smaller deficit in performance on a range of neurobehavioral tasks was observed after melatonin ad-ministration compared with temazepam (38).
We studied patients predominantly with severe COPD. On initial assessment, a lower FVC was found for the placebo group compared to the melatonin group, sug-gesting a higher degree of lung hyperinflation and me-chanical impairment in the placebo group. Although dis-turbed sleep in COPD is thought to be related to the underlying disease process (6), no significant difference in sleep quality between the two groups was found at baseline, as mentioned before. Improved quality of sleep associated with melatonin treatment could not be corre-lated with any improvement in daytime lung function or functional exercise level.
No significant adverse effects were reported by the subjects after melatonin administration. Melatonin has been consumed for many years in several countries where it is available freely or by prescription, without reports of major adverse effects. Recently, a systematic review of 17 ran-domized controlled trials with651 participants confirmed that melatoninis safe for short-term use (three months or less). However, there is a need for further studies assess-ing the safety of long-term melatonin treatment (15). In particular, there has been some concern regarding the effect of prolonged melatonin use on the human reproduc-tive function. A decrease in sperm concentration and mo-tility below normal was found in 2 of 8 men enrolled in a double-blind crossover studyof melatonin treatment (39). In the present study, no objective measures of sleep or daytime sleepiness were obtained. Sleep quality was as-sessed by the PSQI, a questionnaire widely used for this purpose. Previously, melatonin has been shown to im-prove subjective sleep quality in the absence of substantial changes in sleep architecture (13,14). It should be kept in mind that, due to its largely subjective nature, sleep quality correlates with, but is not accurately defined by, sleep labo-ratory measurements. A previous study comparing subjec-tive sleep characteristics assessed by questionnaire with objective measures obtained during polysomnography showed that, although individuals are able to satisfactorily judge time in bed, total sleep time and sleep latency, correlation between sleep quality and objective sleep char-acteristics is less strong (40). In summary, melatonin, as used in this study, has the potential to become a useful tool for the management of sleep problems in COPD patients.
References
1. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176:
532-555.
3. Menezes AM, Perez-Padilla R, Jardim JR, Muino A, Lopez MV, Valdivia G, et al. Chronic obstructive pulmonary dis-ease in five Latin American cities (the PLATINO study): a prevalence study. Lancet 2005; 366: 1875-1881.
4. Weitzenblum E, Chaouat A. Sleep and chronic obstructive pulmonary disease. Sleep Med Rev 2004; 8: 281-294. 5. Santos CEVG, Viegas CAA. Sleep pattern in patients with
chronic obstructive pulmonary disease and correlation among gasometric, spirometric, and polysomnographic vari-ables. J Pneumol 2003; 29: 69-74.
6. McNicholas WT. Sleep in chronic obstructive pulmonary disease. Eur Respir Mon 2006; 38: 325-336. [http:// www.maney.co.uk/series/ers]
7. Breslin E, van der Schans C, Breukink S, Meek P, Mercer K, Volz W, et al. Perception of fatigue and quality of life in patients with COPD. Chest 1998; 114: 958-964.
8. Phillips BA, Cooper KR, Burke TV. The effect of sleep loss on breathing in chronic obstructive pulmonary disease. Chest 1987; 91: 29-32.
9. Kutty K. Sleep and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2004; 10: 104-112.
10. Scheer FA, Czeisler CA. Melatonin, sleep, and circadian rhythms. Sleep Med Rev 2005; 9: 5-9.
11. Claustrat B, Brun J, Chazot G. The basic physiology and patho-physiology of melatonin. Sleep Med Rev 2005; 9: 11-24. 12. Campos FL, da Silva-Junior FP, de Bruin V, de Bruin PF.
Melatonin improves sleep in asthma: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2004; 170: 947-951.
13. Medeiros CA, Carvalhedo de Bruin PF, Lopes LA, Magalhaes MC, de Lourdes SM, de Bruin V. Effect of exog-enous melatonin on sleep and motor dysfunction in Park-inson’s disease. A randomized, double blind, placebo-con-trolled study. J Neurol 2007; 254: 459-464.
14. Brzezinski A, Vangel MG, Wurtman RJ, Norrie G, Zhdanova I, Ben-Shushan A, et al. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Med Rev 2005; 9: 41-50. 15. Buscemi N, Vandermeer B, Hooton N, Pandya R, Tjosvold
L, Hartling L, et al. Efficacy and safety of exogenous melato-nin for secondary sleep disorders and sleep disorders ac-companying sleep restriction: meta-analysis. BMJ 2006; 332: 385-393.
16. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989; 28: 193-213.
17. Johns MW. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991; 14: 540-545. 18. ATS statement: guidelines for the six-minute walk test. Am J
Respir Crit Care Med 2002; 166: 111-117.
19. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995; 152: 1107-1136. 20. Norusis MJ. SPSS for Windows: Base System User’s Guide.
Release 15.0. [Computer program]. 2006.
21. Shilo L, Dagan Y, Smorjik Y, Weinberg U, Dolev S, Komptel B, et al. Effect of melatonin on sleep quality of COPD intensive care patients: a pilot study. Chronobiol Int 2000; 17: 71-76.
22. Pires ML, Benedito-Silva AA, Pinto L, Souza L, Vismari L, Calil HM. Acute effects of low doses of melatonin on the sleep of young healthy subjects. J Pineal Res 2001; 31: 326-332. 23. Zhdanova IV, Wurtman RJ, Lynch HJ, Ives JR, Dollins AB,
Morabito C, et al. Sleep-inducing effects of low doses of melatonin ingested in the evening. Clin Pharmacol Ther 1995; 57: 552-558.
24. Cajochen C, Krauchi K, Danilenko KV, Wirz-Justice A. Eve-ning administration of melatonin and bright light: interac-tions on the EEG during sleep and wakefulness. J Sleep Res 1998; 7: 145-157.
25. Hughes RJ, Sack RL, Lewy AJ. The role of melatonin and circadian phase in age-related sleep-maintenance insom-nia: assessment in a clinical trial of melatonin replacement. Sleep 1998; 21: 52-68.
26. Dawson D, Rogers NL, van den Heuvel CJ, Kennaway DJ, Lushington K. Effect of sustained nocturnal transbuccal melatonin administration on sleep and temperature in eld-erly insomniacs. J Biol Rhythms 1998; 13: 532-538. 27. Waldhauser F, Saletu B, Trinchard-Lugan I. Sleep
labora-tory investigations on hypnotic properties of melatonin. Psy-chopharmacology 1990; 100: 222-226.
28. Arendt J. Importance and relevance of melatonin to human biological rhythms. J Neuroendocrinol 2003; 15: 427-431. 29. Tenn CC, Niles LP. Central-type benzodiazepine receptors
mediate the antidopaminergic effect of clonazepam and melatonin in 6-hydroxydopamine lesioned rats: involvement of a GABAergic mechanism. J Pharmacol Exp Ther 1995; 274: 84-89.
30. Nave R, Herer P, Haimov I, Shlitner A, Lavie P. Hypnotic and hypothermic effects of melatonin on daytime sleep in humans: lack of antagonism by flumazenil. Neurosci Lett 1996; 214: 123-126.
31. Zhdanova IV, Raz DJ. Effects of melatonin ingestion on cAMP and cGMP levels in human plasma. J Endocrinol 1999; 163: 457-462.
32. Edgar DM, Dement WC, Fuller CA. Effect of SCN lesions on sleep in squirrel monkeys: evidence for opponent processes in sleep-wake regulation. J Neurosci 1993; 13: 1065-1079. 33. Dijk DJ, Czeisler CA. Paradoxical timing of the circadian
rhythm of sleep propensity serves to consolidate sleep and wakefulness in humans. Neurosci Lett 1994; 166: 63-68. 34. Liu C, Weaver DR, Jin X, Shearman LP, Pieschl RL, Gribkoff
VK, et al. Molecular dissection of two distinct actions of melatonin on the suprachiasmatic circadian clock. Neuron 1997; 19: 91-102.
35. Cormick W, Olson LG, Hensley MJ, Saunders NA. Noctur-nal hypoxaemia and quality of sleep in patients with chronic obstructive lung disease. Thorax 1986; 41: 846-854. 36. Orr WC, Shamma-Othman Z, Levin D, Othman J, Rundell
OH. Persistent hypoxemia and excessive daytime sleepi-ness in chronic obstructive pulmonary disease (COPD). Chest 1990; 97: 583-585.
37. Zhdanova IV. Melatonin as a hypnotic: pro. Sleep Med Rev 2005; 9: 51-65.
38. Rogers NL, Kennaway DJ, Dawson D. Neurobehavioural performance effects of daytime melatonin and temazepam administration. J Sleep Res 2003; 12: 207-212.
39. Luboshitzky R, Shen-Orr Z, Nave R, Lavi S, Lavie P. Mela-tonin administration alters semen quality in healthy men. J Androl 2002; 23: 572-578.
